Placebo News and Research

RSS

GTx achieves enrollment goal for pivotal Phase III clinical studies of enobosarm

GTx, Inc. today announced that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer patients.

17 Dec 2012

IRB Barcelona, BBVA Foundation organize international conference on biostatistics

Statistics have entered the life sciences and they are here to stay. This science emerged in the XVIII century by the hand of the mathematicians Thomas Bayes and Pierre Simon Laplace and was used by Gregor Mendel to demonstrate his theory on genetic inheritance. Since the 90s with the appearance of large genomic studies, statistics has become a fundamental tool for the analysis and interpretation of biomedical data.

16 Dec 2012

Everolimus therapy might treat Myc-driven lymphoma

Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.

15 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

15 Dec 2012

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

14 Dec 2012

High-dose vitamin D can reduce risk of respiratory tract infections

Treating infection-prone patients over a 12-month period with high doses of vitamin D reduces their risk of developing respiratory tract infection - and consequently their antibiotic requirement. This according to a new study by researchers at Karolinska Institutet and Karolinska University Hospital published in the online scientific journal BMJ Open.

14 Dec 2012

Combination therapy reduces sleep apnea symptoms at altitude

Patients with obstructive sleep apnea can better control their symptoms when traveling to higher altitudes by combining autoadjusted continuous positive airway pressure with acetazolamide, research suggests.

14 Dec 2012

ETA receptor antagonism reduces novel cardiovascular risk factors in patients with CKD

Blocking the receptor for proteins that constrict blood vessels reduces markers of heart-related problems in patients with chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

14 Dec 2012

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the publication of data from its first-in-human Phase 1 study of its NDV-3 vaccine program in the journal Vaccine.

13 Dec 2012

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

13 Dec 2012

Fingolimod associated with modest, rapid increase in macular volume

Patients with multiple sclerosis treated with fingolimod undergo a modest but rapid increase in macular volume, research shows.

13 Dec 2012

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Eli Lilly and Company today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease.

13 Dec 2012

Bumetanide could treat children with severe autism or Asperger's syndrome

Although this therapy is not curative, it nevertheless reduced the autistic disorders' severity in three-quarters of the children. The researchers have filed a request for authorisation to perform a multi-centre European clinical trial in order to determine more precisely the population concerned by this therapy.

13 Dec 2012

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

13 Dec 2012

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.

13 Dec 2012

Industry sponsored clinical trials present a more favourable picture of reported findings

Studies reporting the results of industry sponsored clinical trials present a more favourable picture of the effects of drugs and medical devices than those reporting on non-industry sponsored trials, according to a new Cochrane systematic review. The researchers call for a rethink of the way that industry bias is handled in medical guidelines and reviews.

12 Dec 2012

Acetazolamide plus autoCPAP may reduce insomnia and control sleep apnea at high altitudes

For individuals with obstructive sleep apnea traveling to higher altitudes (which may exacerbate symptoms), use of a combination therapy resulted in improvement in symptoms including reduced insomnia and better control of sleep apnea, according to a preliminary study published in the December 12 issue of JAMA.

12 Dec 2012

Tiotropium benefits patients with chronic obstructive pulmonary disease

In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD), tiotropium bromide (tiotropium in brief) is one of the drugs available that can be prescribed for inhalation. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether tiotropium offers a perceptible advantage to patients compared to a dummy medication (placebo) and to other COPD drugs.

12 Dec 2012

Naltrexone may help avoid weight gain among women smokers

A medication being tested to help smokers kick the habit also may help avoid the weight gain that is common after quitting but only in women, according to a study published in the December issue of Biological Psychiatry. This is the first medication shown to reduce weight gain for up to one year in women smokers who quit.

11 Dec 2012

Placebo News and Research

GTx achieves enrollment goal for pivotal Phase III clinical studies of enobosarm

IRB Barcelona, BBVA Foundation organize international conference on biostatistics

Everolimus therapy might treat Myc-driven lymphoma

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

High-dose vitamin D can reduce risk of respiratory tract infections

Combination therapy reduces sleep apnea symptoms at altitude

ETA receptor antagonism reduces novel cardiovascular risk factors in patients with CKD

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Fingolimod associated with modest, rapid increase in macular volume

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Bumetanide could treat children with severe autism or Asperger's syndrome

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Industry sponsored clinical trials present a more favourable picture of reported findings

Acetazolamide plus autoCPAP may reduce insomnia and control sleep apnea at high altitudes

Tiotropium benefits patients with chronic obstructive pulmonary disease

Naltrexone may help avoid weight gain among women smokers

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News